New Percutaneous Devices to Prevent Embolism in Atrial Fibrillation

Patients with atrial fibrillation (AF) unsuitable for anticoagulation because of bleeding risk, require other strategies to prevent stroke. For some years, there have been in the market (limited to some places; not as part of the regular agenda of cardiologists and hematologists) devices to occlude the atrium that have been proved safe and effective.

Proliferan los dispositivos para el reemplazo valvular mitral por catéter

These new devices are a completely different. They are permanent filters placed directly in both carotid arteries and are designed to capture >1.4 mm emboli.

This non-randomized, multicenter study has shown for the first time in humans the feasibility and safety of implanting this bilateral filter in patients with AF, high bleeding risk (CHA2DS2-VASc ≥ 2) unsuitable for anticoagulation, with common carotid arteries between 4.8 and 9.8 mm and stenosis < 30%.


Read also: The First Antidote Against Ticagrelor Is a Rapid-Acting, Extended Effect Agent in Preliminary Results.


Under ultrasound guidance and after direct puncture of the carotid with a 24 G needle, the filter is unfurled in the artery with a motorized system. All patients received aspirin and clopidogrel for 3 months, and aspirin thereafter.

Primary end points were procedural success (correct implantation of filter in both carotids) and composite of events at 30 days (death, stroke, major bleeding, filter migration, thrombus formation or stenosis). Ultrasound follow-up was carried out immediately after procedure, prior to discharge, at one week, one month and 3, 6 and 12 months.

The study included 25 patients with mean CHA2DS2-VASc of 4.4 ± 1, half of them had presented prior embolism.

Procedural success was 92%, in one patient, the device could be deployed only in one artery. There were no procedure related major events, only 20% of hematomas were puncture related.


Read also: El primer antídoto del ticagrelor es rápido y de acción prolongada en los resultados preliminares.


After 6 months, no patients formed thrombi inside the filter, but 4 did capture emboli (one bilateral); none of these patients developed symptoms.

In all patients, thrombi were reabsorbed using low molecular weight heparin for some time. There were 2 minor strokes, but not in carotid territory.

Conclusión

The implantation of permanent carotid filters to prevent strokes is technically feasible and safe.

Original Title: A Percutaneous Permanent Carotid Filter for Stroke Prevention in Atrial Fibrillation: The CAPTURE Trial.

Reference: Vivek Y et al. Journal of the American College of Cardiology (2019). ACCEPTED MANUSCRIPT.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...